to page content
to site navigation
The Resource Center has all the info you'll need From content to user feedback, the resource center has the information you need for every level of the entrepreneurial process.
Global growth is essential for entrepreneurial companies but must be managed to overcome challenges such as language barriers and tax-related paperwork, says the founder of a Harley-Davidson licensee.
Mir Imran founded InCube Laboratories in 1995 to focus on his passion: creating medical device solutions that change the standard of care in critical healthcare markets. Mir began his career as a med-tech entrepreneur in
the late 1970's. Over the decades, he has become one of the world's most successful inventors, entrepreneurs and investors in healthcare. Mir now holds more than 200 issued patents - and is perhaps most well known for his pioneering
contributions to the first FDA-approved Automatic Implantable Cardioverter Defibrillator. Mir's current crop of inventions includes advanced treatments for neural aneurysms, epilepsy, ulcerative colitis, obesity and chronic pain, among
others. Most of these will enter clinical trials in the 2008 to 2010 timeframe. As an entrepreneur, Mir has founded over 20 medical device companies, including: Vidamed (acquired by Medtronic), Physiometrix, Cardiac Pathways, Advanced
Cytomextrix (acquired by Oncotech 1997), Percusurge (acquired by Medtronic 2001), Reflow, Inc. (acquired 1999), Safeview (acquired by L3 2006) Intrapace (founded 2001), Spinal Modulation (founded 2005) and Zonare (founded 1999). As an
investor, Mir serves as the Life Science Venture Partner for DFJ ePlanet, where he has led 9 investments in a range of promising ventures around the globe. Mir is also an active angel investor, with a portfolio based around both medical
and pharmaceutical ventures. Mir currently holds board seats with Bodymedia, Cardiovasc, Intrapace, Egeen International, Spinal Modulation, ZARS and Zonare. Mir holds an MS in Bio-Engineering and a BS in Electrical Engineering from
Rutgers, where he spent three years as a Research Specialist.
The Institute of Medicine (IOM) released a report recommending the 510(k) process be scrapped. Read more about the medical device industry’s reaction.
In the race to get new medical devices to market, companies encounter FDA speed bumps that slow down the process. But would we really be willing to accept the risks that would accompany fast FDA approvals?
Dr. Khanna has been a member of the faculty of the Harvard Business School since 1993, where he studies, and works with, multinational and indigenous companies and investors in emerging markets worldwide. He has served
as course head of the required Strategy course in the Harvard MBA program, and chaired the executive education program on Strategy, Leadership & Governance. Currently, he teaches in Harvard's comprehensive general management executive
education programs. He earned a Bachelors of Science in Engineering degree from Princeton University in 1988, summa cum laude, Phi Beta Kappa, and a Ph.D. in Business Economics from Harvard University in 1993. His current research focuses
on understanding the drivers of entrepreneurship worldwide. As part of the Emerging Giants project, he seeks to understand how to build world-class companies from emerging markets worldwide. A related project, The Dragon and the Elephant,
zeros in on China and India, and identifies best practices for local entrepreneurs and multinationals operating in each of these two countries. His scholarly work is published in a range of journals over the past fifteen years. During this
time, he has continued to serve as a co-editor of several prestigious economics and management journals. A forthcoming book, Billions of Entrepreneurs: How China and India are Reshaping their Futures and Yours, will be published by Harvard
Business School Press (Penguin in South Asia) in 2007. Numerous articles in the Harvard Business Review (e.g. Emerging Giants: Building World Class Companies in Emerging Markets, 2006) and Foreign Policy (e.g. Can India Overtake China?,
2003) distil the implications of this research for practicing managers. Professor Khanna's work has been profiled in news-magazines around the world, including The Wall Street Journal, The Economist, the Far Eastern Economic Review, and
newspapers in China, India, and el
Vinod grew up dreaming of being an entrepreneur. He was raised in an Indian Army household with no business or technology connections. When, at age 16, he first heard about Intel, he dreamt of starting his own technology
company. Upon graduating with a Bachelors in Electrical Engineering from the Indian Institute of Technology, Delhi, he tried to start a soy milk company to service the many people in India who did not have refrigerators. He then came to
the US and got his Masters in Biomedical Engineering at Carnegie-Mellon University. His startup dreams attracted him to Silicon Valley where he got an MBA at Stanford University in 1980. In 1982, Khosla started Sun Microsystems to build
workstations for software developers. At Sun he pioneered "open systems" and RISC processors. Sun was funded by long time friend and board member John Doerr of Kleiner Perkins Caufield & Byers. In 1986 he switched sides and joined
Kleiner Perkins where he was a general partner. There, he worked with Nexgen/AMD, Juniper, Excite, and many other ventures. In 2004, Khosla formed Khosla Ventures. Khosla Ventures offers venture assistance, strategic advice and capital to
entrepreneurs. The firm helps entrepreneurs extend the potential of their ideas in both traditional venture areas like the Internet, computing, mobile, and silicon technology arenas but also supports breakthrough scientific work in clean
technology areas such as bio-refineries for energy and bioplastics, solar, battery and other environmentally friendly technologies.
Should the U.S. Food and Drug Administration protect the public or drive innovation? One industry leader gives us his take on the future of the FDA.
Randy Komisar joined Kleiner Perkins Caufield and Byers in 2005 as a partner. For several years prior Randy has partnered with entrepreneurs creating businesses with leading edge technologies. He was a co-founder of
Claris Corporation, served as CEO for LucasArts Entertainment and Crystal Dynamics, and acted as a "virtual CEO" for such companies as WebTV, Mirra and GlobalGiving. He was a founding Director of TiVo where he is currently chairman of the
Nominating and Governance Committee. Earlier Randy served as CFO of GO Corporation and Senior Counsel for Apple Computer, following a private practice in Technology Law. Randy holds a BA in Economics from Brown University and a JD form
Harvard Law School. He is a Consulting Professor of Entrepreneurship at Stanford University and author of the best-selling book The Monk and the Riddle, as well as several articles on leadership and entrepreneurship. Randy frequently
speaks here and abroad on such topics.
Chairman and Chief Executive Officer of Juniper Networks since 1996, Scott Kriens built and led the team from its early days of product development to its current broad commercial success. Prior to joining Juniper
Networks, Scott was a co-founder and officer of StrataCom, Inc., in both operations and sales capacities from 1986 to 1996. He also serves as a Director of VeriSign, Inc. and Equinix, Inc. Kriens holds a B.A. degree in Economics from
California State University, Hayward.
What if we could take the top talent coming out of colleges and universities today, those that tend to feed into law school, med school, Wall Street and consulting, and put them in startups all over the country? Imagine the job growth possibilities we could create in the country just by giving recent graduates a taste of that entrepreneurial bug. Now, what if I told you there's an organization trying to do just that. Enter--Venture for America.
Want to get connected? Sign up to receive regular news, polls and updates from The Kauffman Foundation.